Shots:
- The NMPA has approved Nucala as an add-on therapy with intranasal corticosteroids in CRSwNP adults with inadequately controlled disease. It is approved for patients (≥12yrs.) as an add-on treatment of severe eosinophilic asthma & for adults having eosinophilic granulomatosis with polyangiitis
- Approval was based on 2 P-III studies: MERIT assessing Nucala vs PBO in Japanese, Chinese & Russian subjects for 52wks. and SYNAPSE involving >400 subjects with this indication
- MERIT study, involving 163 patients, showed significantly improved nasal obstruction VAS score (mean difference: -1.43), QoL by SNOT-22 (difference: -10.63) & loss of smell VAS score (difference: -0.82) as well as reduced nasal polyp score at wk.52
Ref: GSK | Image: GSK
Related News:- GSK Reports the Data from the P-III (FIRST-ENGOT-OV44) Study Evaluating Zejula and Jemperli in 1L Advanced Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
